胃癌患者5-氟尿嘧啶用药安全性Meta分析

Meta Analysis on the Safety of Using 5-FU in Patients with Gastric Carcinoma

目的系统评价胃癌患者使用5-氟尿嘧啶(5-FU)的安全性,为临床合理用药提供参考。方法检索国内外发表的关于5-FU治疗胃癌随机对照试验的中英文文献,制订文献纳入及排除标准,对纳入文献进行统计和分析。结果共检索文献794篇,最终纳入11篇。纳入研究经统计、分析得出,5-FU与双药联用比较,血小板减少、腹泻发生率显著低于对照组,口腔黏膜炎发生率显著高于对照组;与三药联用比较,白细胞和血小板减少发生率显著低于对照组。漏斗图显示,纳入研究的发表偏倚较小。结论 5-FU作为常用的胃癌化学治疗药物,安全性较好。

Objective To systematically evaluate the safety of using 5-FU in the patients with gastric carcinoma to provide reference for rational clinical drug use. Methods The Chinese and English literatures of the randomized controlled trial（RCT）on 5-FU in the treat- ment of gastric carcinoma were retrieved. The inclusion and the exclusion standards were formulated. The included RCT were performed the statistical analysis. Results Totally 794 articles were retrieved and 11 articles were finally included. The statistical analysis found that comparing 5-FU with the 2-drug combination, the occurrence rate of thrombocytopenia and diarrhea were lower than that in the control group; the occurrence rate of oral mucositis was significantly higher than that in the control group. Compared with the 3-drug combination, the occurrence rate of leueopenia and thrombocytopenia was significantly lower than that in the control group. The funnel plot showed that the publication bias of the included RCT was small. Conclusion 5-FU as a commonly used chemotherapeutic drug of gastric carcinoma has better safety.